Rising Global Dermatologic Demand Will Fuel Future Success

Key Takeaways

• Rapid adoption of EMROSI and expanded insurance coverage are driving strong revenue growth and positioning the company to benefit from increased dermatology demand.
  
• Financial discipline and operational leverage support profitability while mitigating risks from legacy products, enhancing earnings resilience and reducing potential dilution.
  
• Heavy dependence on a few core brands, vulnerability to generic competition, high operating costs, and limited R&D investment threaten future revenue stability and profitability.

Catalysts

Focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.

• The rapid penetration and accelerating prescription growth of EMROSI, a new oral rosacea treatment, is tapping into increasing global demand for dermatologic care, fueled by an aging population and heightened consumer focus on skin health; sustained prescription ramp and expanding provider adoption are expected to drive significant near
• and long-term revenue growth.
  
• The swift increase in payer access for EMROSI (from 30% to 65% of commercial lives within a few months) and ongoing efforts to secure broader formulary placements directly address improving healthcare access and coverage, setting up further gains in patient affordability and resulting in higher script volumes and future revenues.
  
• Journey Medical is increasing operational leverage via an established commercial and sales infrastructure, enabling margin expansion as new product revenues, particularly from EMROSI, scale while operating expenses remain stable-positively impacting net margins and speeding the path to sustainable profitability.
  
• The company's strategic allocation of resources (minimal cash burn, disciplined R&D, and controlled OpEx) provides financial flexibility to support product launches and withstand legacy product headwinds, which should enhance earnings resilience and reduce dilution risk.
  
• Early clinical and prescriber feedback, strong commercial traction, and the potential for EMROSI to become standard of care in rosacea signal an ability to capitalize on premium pricing for innovative therapies, supporting long-term revenue growth and enhanced gross margins through sustained market differentiation.

Journey Medical Future Earnings and Revenue Growth

Assumptions

• Analysts are assuming Journey Medical's revenue will grow by 49.1% annually over the next 3 years.
• Analysts assume that profit margins will increase from -15.5% today to 33.6% in 3 years time.
• Analysts expect earnings to reach $62.9 million (and earnings per share of $2.7) by about August 2028, up from $-8.7 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $69.6 million in earnings, and the most bearish expecting $27.2 million.
• In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 6.5x on those 2028 earnings, up from -19.7x today. This future PE is lower than the current PE for the US Pharmaceuticals industry at 19.1x.
• Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.78%, as per the Simply Wall St company report.

Journey Medical Future Earnings Per Share Growth

Risks

• Intense generic competition has already caused a significant decline in Accutane revenue and may similarly threaten other legacy products as well as EMROSI over time, putting continued pressure on overall revenue and gross margins.
  
• The company remains heavily reliant on the early success and continued momentum of EMROSI and a limited portfolio of core growth brands; if EMROSI fails to maintain rapid uptake or if market dynamics (like payer negotiations) shift unfavorably, long-term revenue growth and profitability could be materially limited.
  
• There is ongoing uncertainty in converting high prescription volumes into sustainable revenue, due to continued high utilization of patient assistance programs, delayed payer reimbursements, and gradual payer formulary adoption, which can weaken earnings visibility and impact net margins.
  
• Operating expenses, particularly SG&A tied to EMROSI commercialization, have increased and could remain elevated if the company must continue aggressive marketing to combat future competition or expand access, thus limiting the anticipated leverage and slowing the path to positive EBITDA and net profitability.
  
• A lack of investment in internal R&D-evidenced by nil R&D spend in recent quarters-may constrain future innovation and pipeline growth, restricting the company's ability to diversify its portfolio and driving long-term dependence on a small number of products, increasing future risks to revenue and earnings stability.

Valuation

• The analysts have a consensus price target of $11.5 for Journey Medical based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $13.0, and the most bearish reporting a price target of just $10.0.
  
• In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $187.0 million, earnings will come to $62.9 million, and it would be trading on a PE ratio of 6.5x, assuming you use a discount rate of 6.8%.
  
• Given the current share price of $7.07, the analyst price target of $11.5 is 38.5% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.